1Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy[ J]. J Clin Oncol, 1994,12:206 - 212.
2Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow-up of renal cell carcinoma based on pathological stage[J]. J Urol, 1995, 154:28-31.
3Rouviere O, Bouvier R, Negrier S, et al. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up[ J]. Nat Clin Pract Oncol, 2006, 3: 200 - 213.
4Messing EM, Manola J, Wilding G, et al. Phase Ⅲ study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial[J]. J Clin Oncol, 2003, 21 (7):1214- 1222.
5Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial [ J ]. J Clin Oncol, 2003,21:3133 - 3140.
6Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma [ J ]. J Clin Oncol, 2002,20 ( 1 ) : 289 - 296.
7Coppin C, Porzsoh F, Awa A, et al. Immunotherapy for advanced renal cell cancer [ J ]. Cochrane Database Syst Rev, 2006,2:61 - 65.
8Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma [J]. N Engl J Med, 2007, 356(2):125-134.
9Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J]. N Engl J Med 2007,356(2) :115 - 124.
10Hudes G ,Carducei M ,Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [ J ]. N Engl J Med. 2007,356( 22 ) :2271 - 2281.
二级参考文献9
1Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma: results of a multieenter SCAPP1 trial. Ann Oneol, 1996, 7:525-528.
2Donskov F, yon der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 : 1997-2005.
4Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 1997, 80: 1198- 1220.
5Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125- 134.
6Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 : 115-124.
7Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000, 6 : S55-57.
8Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995, 13:688-696.
9Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion aIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer, 2004, 90: 1156-1162.
4Negrier S. Better survival with interleukn-2-based regimens? Possibly only in highly selected patients [ J ]. J Clin Oncol, 2004, 22 : 1174 - 1176.
5Pavone L, Andrulli S,Santi R, et al. Long-term treatment with low doses of interleukn-2 and interferon-alpha: immunological effects in advanced renal cell cancer[ J]. Cancer Immunol Immunother, 2001, 50:82-86.
6Culine S, Iborra F, Mottet N, et al. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma:Results of a French regional experience in Languedoc [ J ]. Am J Clin Oncol, 2006, 29(2) :148 -152.
7Martel CL, Lara PN. Renal cell carcinoma current status and future directions [J].Crit Rev Oncol Hematol, 2003, 45:177 - 190.
8Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced dear-cell renal-cell carcinoma[ J ]. N Engl J Med, 2007, 356: 125 - 134.
9Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [ J ]. N Engl J Med, 2007,356(2) :115 - 124.
10Hudes G, Cardueci M, Tomczak P, et al. Temsimlimus, interferon alfa, or both for advanced renal-cell carcinoma[J].N Engl J Med, 2007, 356:2271 - 2281.
